Previous Article | Next Article ![]()
Journal of Virology, March 2008, p. 2056-2064, Vol. 82, No. 5
0022-538X/08/$08.00+0 doi:10.1128/JVI.01803-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

i
in-
ain,1,
Zsolt Ruzsics,1
Juergen Podlech,2
Ivan Bubi
,3
Carine Menard,1
Stipan Jonji
,3
Matthias J. Reddehase,2 and
Ulrich H. Koszinowski1*
Max von Pettenkofer Institute, LMU, 80336 Munich, Germany,1 Institute for Virology, Johannes Gutenberg University, 55131 Mainz, Germany,2 Department of Histology and Embryology, Medical Faculty University of Rijeka, 51000 Rijeka, Croatia3
Received 16 August 2007/ Accepted 12 December 2007
Genes that inhibit apoptosis have been described for many DNA viruses. Herpesviruses often contain even more than one gene to control cell death. Apoptosis inhibition by viral genes is postulated to contribute to viral fitness, although a formal proof is pending. To address this question, we studied the mouse cytomegalovirus (MCMV) protein M36, which binds to caspase-8 and blocks death receptor-induced apoptosis. The growth of MCMV recombinants lacking M36 (
M36) was attenuated in vitro and in vivo. In vitro, caspase inhibition by zVAD-fmk blocked apoptosis in
M36-infected macrophages and rescued the growth of the mutant. In vivo,
M36 infection foci in liver tissue contained significantly more apoptotic hepatocytes and Kupffer cells than did revertant virus foci, and apoptosis occurred during the early phase of virus replication prior to virion assembly. To further delineate the mode of M36 function, we replaced the M36 gene with a dominant-negative FADD (FADDDN) in an MCMV recombinant. FADDDN was expressed in cells infected with the recombinant and blocked the death-receptor pathway, replacing the antiapoptotic function of M36. Most importantly, FADDDN rescued
M36 virus replication, both in vitro and in vivo. These findings have identified the biological role of M36 and define apoptosis inhibition as a key determinant of viral fitness.
Published ahead of print on 19 December 2007.
Present address: Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»